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Summary Previous studies have shown both similar and distinct inflammatory
changes in atopic and nonatopic asthma. This study was set to investigate the
bronchial inflammatory cell infiltrate and subepithelial basement membrane (BM)
tenascin deposition in subjects with newly diagnosed asthma and bronchial
hyperresponsiveness (BHR). Seventy-nine asthmatic subjects (age 18–60 years) were
recruited and 58 were atopic according to skin prick testing. The patients recorded
asthma symptoms and peak flow measurements for 14 days. Lung function and BHR
were measured by spirometry and histamine challenge. Serum eosinophil cationic
protein (ECP) and blood eosinophils were assessed. Fiberoptic bronchoscopy was
performed to obtain bronchial biopsies. Serum ECP was higher in the atopic group but
eosinophil counts did not differ. There were no differences in inflammatory cells
studied (activated eosinophils, T-lymphocytes, mast cells or macrophages) between
nonatopic and atopic subjects. BM tenascin layer was significantly thicker in atopic
compared with nonatopic subjects (7.6 vs 6.3 mm, P ¼ 0:007). The thickness of
tenascin correlated with eosinophil, T-lymphocyte, and macrophage counts, as well
as with IL-4-positive cell counts and the correlation was seen only in atopic
asthmatics. These findings suggest that inflammatory cells may have a regulatory role
in tenascin expression in atopic asthma.









Asthma is an inflammatory disorder of the airways,
which is characterized by reversible airways ob-
struction causing dyspnea and bronchial hyperre-
sponsiveness (BHR) to specific and nonspecific
stimuli. The pathological features in the asthmatic
airways are infiltration of inflammatory cells in the
mucosa, especially eosinophils and T-lymphocytes,
epithelial shedding, goblet cell hyperplasia, and
thickening of the basement membrane (BM). These
events are seen even in newly diagnosed asthma.1
Tenascin is a large extracellular matrix (ECM)
protein that is expressed in the BM zone during
embryonic development, tissue repair, and onco-
genesis.2 Its expression in bronchial BM is elevated
in asthma compared with nonasthmatic nonatopic
control subjects; and the thickness of tenascin
immunoreactivity in atopic asthmatics decreased
ARTICLE IN PRESS
*Corresponding author. Hospital District of Helsinki and
Uusimaa, P.O. Box 100, HUS 00029, Finland. Tel.: þ 358-9-471-
71200; fax: þ 358-9-471-71206.
E-mail address: lauri.laitinen@hus.fi (A. Laitinen).
0954-6111/03/$ - see front matter & 2003 Elsevier Ltd. All rights reserved.
doi:10.1016/S0954-6111(03)00136-7
Respiratory Medicine (2003) 97, 1045–1051
by treatment with budesonide.3 The role of
increased tenascin accumulation in the asthmatic
bronchial BM is yet unknown. It may contribute to
the ongoing epithelial injury and repair in asth-
matic inflammation as it contributes to the wound
healing process.4
Asthma is divided into two subgroups according
to the atopic status. The variants are atopic
(atopic) asthma and nonatopic (nonatopic) asth-
ma.5 The clinical features of these subtypes of
asthma are distinct. Patients with nonatopic
asthma are more frequently females and their
disease has more severe clinical course and the
family history of allergy or asthma is often lacking.6
Atopic asthma is IgE-mediated with raised IgE-
antibodies to allergens, whereas in nonatopic
asthma IgE-mediated reactions cannot be de-
tected.7 Nonatopic asthmatics are less hyperre-
sponsive to inhaled adenosine-50-monophosphate8
and they have normal concentrations of exhaled
nitric oxide opposed to higher than normal con-
centrations in atopic asthmatics.9 These findings
suggest that bronchial inflammatory changes in
atopic and nonatopic asthma are different. How-
ever, Humbert and coworkers found similarities in
chemokine and cytokine expression in airway
mucosa both in nonatopic and atopic asthma.10
There is preliminary evidence that airway macro-
phage infiltration and function are not similar in
nonatopic and atopic asthma.6 Amin et al. found
that tenascin layer in subepithelial BM was thicker
in atopic compared with nonatopic asthmatics
showing a structural difference in the bronchial
mucosal level in these distinct asthmatic sub-
groups.11
The aim of the present study was to compare
inflammatory cell pattern and BM tenascin in
bronchial mucosa of atopic and nonatopic subjects
with newly diagnosed asthma and BHR.
Methods
Patients
Currently, nonsmoking subjects (nonsmokers or ex-
smokers 42 years and o10 pack years) aged
between 18 and 60 years were recruited to the
study. Asthma was diagnosed according to the
American Thoracic Society (ATS) guidelines12 less
than 2 years earlier. A 15% reversibility in FEV1 or
peak flow (PEF) or a 20% diurnal variation in PEF
were recorded at least 12 months prior entering the
study. Subjects were currently symptomatic and all
of them were hyperresponsive (PD15FEV1 to hista-
mineo0.4mg). A the time of selection to the study
the FEV1 was more than 60% of the national
predicted value.13 Before entering the study, the
participants received only inhaled short-acting b2-
agonist and they had no inhaled or oral steroids
during the last 2 months, no long-acting b2-agonist
or other asthma medication during the last 4 weeks
or any anti-histamine for 2 weeks. The patients
with serious uncontrolled systemic diseases, cur-
rent use of beta-blockers, respiratory tract infec-
tions, or asthma exacerbation within 4 weeks were
excluded. The atopic status was assessed by skin
prick testing with a panel of 10 common aeroaller-
gens. The patients who were skin prick test positive
for a seasonal allergen were not allowed to
participate in the study during the season of their
allergy. All patients gave informed, written consent
before commencing the study. The study was
approved by the local ethics committee.
Patients monitored their PEF, symptoms, and
rescue medication need (salbutamol pMDI 0.1mg/
dose: Ventolines) for a period of 2 weeks before the
bronchoscopy. The daytime symptoms were re-
corded on the diary: from 0 as no symptoms to 5
as incapacitating symptoms. The nighttime symp-
toms were recorded similarly, but from 0 to 4. PEF
was measured with a mini-Wright peak flow meter
(Clement-Clarke, Harlow, UK) in the morning and
evening. The patient recorded the best of three
measurements. The inhalation of rescue bronchodi-
lator was avoided 4h before the PEF measurement.
FEV1 and forced vital capacity (FVC) were
measured with a Vitalograph TM spirometer
(Fleisch, Bucks, UK) before entering the study to
evaluate the entry criteria and in the morning on
the day of bronchoscopy following the ATS stan-
dard.12 FEV1 and FVC assessed again 15min later
after inhalation of 0.2mg of salbutamol to test for
reversibility. Histamine challenge was performed
2–4 weeks before bronchoscopy with the use of an
inhalation-synchronized, dosimetric nebulizer
(Spira Elektro 2, Respiratory Care Center, H-
.ameenlinna, Finland).14
Blood samples were collected before the
bronchoscopy to determine blood eosinophils and
eosinophil cationic protein (ECP) in the serum. The
number of blood eosinophils was counted in B .urkes
chamber after staining with floxine. Serum ECP was
measured by an immunofluorometric method on a
fully automated immunoanalyzer UniCap 100 (Phar-
macia & Upjohn, Uppsala, Sweden). The normal
range for serum ECP was considered from 2 to
16 mg/l.
Fiberoptic bronchoscopy was performed accord-
ing to the international standard.15 Premedication
included oral oxazepam 30mg, intramuscular
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atropine 0.5mg, and inhaled salbutamol 0.2mg.
Lignocaine was used as local anesthetic up to a
maximum dose of 500mg. The bronchoscope
(Olympus XT20, Tokyo, Japan) was introduced
orally into the right main bronchus. The biopsy
specimens were taken using cupped forceps (FB-
36C E, Olympus, Japan) from unattached areas of
bronchial mucosa: inside the right upper lobe, at
the opening of the right middle lobe, and from one
of the basal segment bronchi of the right lower
lobe.
Sample processing and immunohistochemistry
The biopsy specimens were immediately snap
frozen in liquid nitrogen, stored at 701C and
processed as previously described.3
Mast cells, macrophages, T-lymphocytes, as well
as their subsets, and neutrophils were identified
with the following mouse monoclonal antibodies
(Mab’s) mast cell tryptase clon AA1 (1:500),
BerMac3 (1:50), anti-CD3 (1:1000), anti-CD4
(1:100), anti-CD8 (1:1000) and anti-neutrophil
elastase clone NP57 (1:2000, ELA) from Dako A/S
(Glostrup, Denmark), respectively. To identify IL-4-
positive cells mouse monoclonal anti-human IL-4
(1:50) from Gemzyme Diagnostics (Cambridge, MA,
USA). The cells were visualized with the alkaline
phospatase anti-alkaline phosphatase technique in
accordance with the manufacturer’s instructions
(Dako A/S, Glostrup, Denmark). To detect eosino-
phils, the frozen sections were fixed with 4%
paraformaldehyde in phosphate buffer at þ 201C
for 20min, and then exposed 30min to normal
rabbit serum 1:10 following the incubation with the
primary Mab EG2 (1:50, Kabi Pharmacia Diagnostics
AB, Uppsala, Sweden) over night at þ 41C and
processed for the avidin–biotin–peroxidase method
in accordance with the manufacturer’s instruc-
tions. The sections were examined and photo-
graphed under a Leitz Dialux 22 EB light
microscope. Photographic slides were projected
onto a calibrated digitizing tablet (Kurta IS/THREE;
Kurta Corp., Phoenix, AZ, USA). The density of
inflammatory cells in the entire sections was
computed with the Autocad program 10.1 (Auto-
desk Inc., Sausalito, CA, USA) as described pre-
viously.3 Tenascin was detected applying
immunofluorescence technique with mouse Mab
100EB2 (Locus Genex, Helsinki, Finland). Areas
containing cross-sections of the BM were photo-
graphed using Leitz Aristoplan microscope,
equipped with appropriate filters, and the thick-
ness of the immunoreactivity was measured semi-
automatically using a computerized image-analysis
program as described earlier.3 Negative controls
were provided by omitting the primary Mab or
replacing it with an irrelevant one.
Statistical analysis
Comparisons between atopic and nonatopic subject
groups were performed with Student’s t-test or
Mann–Whitney U-test when appropriate. Correla-
tion coefficients (r) were calculated with Spear-
man’s rank method. Two-tailed P values o0:05
were considered significant.
Results
A total of 79 patients were included to the study.
Twenty-one of them were skin prick negative and
considered as nonatopic asthmatic. The patients
with nonatopic asthma were significantly older but
no other significant differences were seen in the
demographic or lung function data (Table 1).
Asthma duration was similar in both groups. The
median daytime symptom score was higher in
nonatopic asthmatic subjects (P ¼ 0:03), but the
use of rescue medication was not increased
compared with atopic subjects. Serum ECP was
higher in atopic subjects (Table 1). No difference
was seen in blood eosinophil counts between
nonatopic and atopic asthma.
Bronchoscopy and bronchial biopsies were well
tolerated by all patients. Assessable bronchial
biopsies were obtained from 63 to 74 subjects for
each immunohistochemical staining. In five sub-
jects the biopsy samples were not of appropriate
quality for the analysis, and in nine subjects, the
assessable material was sparse and not sufficient
for all analyses intended. In the entire study group
the subepithelial BM tenascin layer thickness
correlated positively with the densities of activated
eosinophils, CD3þ T-lymphocytes, CD4þ T-lym-
phocytes, CD8þ T-lymphocytes and, macrophage,
but not with mast cells or neutrophils (Table 3).
Neither blood eosinophils nor serum ECP correlated
significantly with FEV1, PD15FEV1, inflammatory
cell counts, or tenascin layer thickness.
There was no significant difference between
nonatopic and atopic subjects for the inflammatory
cell counts (Table 2). The thickness of subepithelial
BM tenascin layer was significantly greater in atopic
subjects (7.6 vs 6.3 mm, P ¼ 0:007) (Fig. 1). In
atopic subjects, the thickness of tenascin layer
correlated significantly correlations with most of
the inflammatory cell types studied with exception
for mast cells, whereas in nonatopic subjects, a
positive correlation was seen only in CD8þ cells
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(Table 3). EG2þ cells correlated negatively with
PD15FEV1 in atopic subjects (r ¼ 0:37; P ¼ 0:007)
but not in nonatopic subjects (r ¼ 0:01; P ¼ 0:95).
Discussion
This study reports features of inflammatory
changes in bronchial mucosa in a large sample of
subjects with newly diagnosed asthma and with
BHR. Most of the patients had not received any
anti-inflammatory treatment, and all had been only
on rescue b2-agonists for at least 4 weeks before
entering the study. We observed a correlation of
subepithelial tenascin layer thickness and inflam-
matory cell infiltration in airway mucosa. This
correlation appeared to be more evident in the
atopic asthmatic subjects. The inflammatory cell
densities in the bronchial mucosa did not distin-
guish nonatopic asthmatics from atopic asthmatics,
but the subepithelial BM tenascin deposition was
significantly higher in atopic asthmatics.
ECM provides a physical framework for cells
during tissue morphogenesis, homeastasis, and
remodeling. Tenascin is an oligomeric glycoprotein
that is an important component of ECM. Tn
expression is restricted normally to embryonic
development. In adult tissues it is expressed only
in pathological states or normal reparatory
processes as in wound healing and inflammation.16
Its re-expression in the bronchial subepithelial BM
of asthmatic patients reflects ongoing injury–repair
process. The mechanisms behind the upregulation
of tenascin expression in the airways is mostly
unknown. Tenascin expression was induced by
TGF-b and TNF-a in cultured bronchial epithelial
cells.17,18 Elevated TGF-b levels have been shown
in the bronchoalveolar lavage fluid in asthmatic
patients.19 In the present study, tenascin layer
thickness correlated with inflammatory cell densi-
ties in the airway mucosa, suggesting that tenascin
expression in asthma is associated closely with the
extent of the inflammatory process. We observed
the strongest correlation in EG2þ cells, but also T-
lymphocytes and macrophages correlated signifi-
cantly with tenascin thickness. Eosinophils are the
main effector cells in asthma. By releasing cyto-
toxic protein such as ECP, major basic protein,
eosinophil protein, and eosinophil peroxidase,
eosinophils orchestrate the desquamation and
destruction of bronchial epithelium.20 This injury
caused by eosinophils may induce the expression of
tenascin in the bronchial mucosa. Amin et al.11
observed that atopic asthmatics had a thicker BM
tenascin than nonatopic asthmatic or healthy
controls. They also found a negative relationship
between epithelial integrity and airway eosinophils
in atopic asthmatics. These findings along with
our own results of tenascins’ relationship with
ARTICLE IN PRESS
Table 1 Clinical characteristics of the study subjects.
Nonatopic asthma (n ¼ 21) Atopic asthma (n ¼ 58) All (n ¼ 79)
Age (years)w 44 (22–58)* 33 (18–61) 36 (18–61)
Male/female 9/12 24/34 33/46
Asthma duration (years)w 0.25 (0.02–1.67) 0.36 (0–2) 0.33 (0–2)
FEV1 (L)
w 2.90 3.15 3.08
(1.83–4.38) (1.87–4.43) (1.83–4.43)
Post-BDFEV1 (L)
w 3.17 3.50 3.41
(1.95–4.61) (2.25–4.95) (1.95–4.95)
FEV1 reversibility (%)
w 9.9 11.6 11.2
(3.9–24.8) (1.7–56.4) (1.7–56.4)
PD15FEV1 (mg of histamine)
w 0.15 0.13 0.13
(0.002–0.37) (0.001–0.34) (0.001–0.37)
Mean morning PEF (L/min)w 449 455 453
(310–630) (232–661) (231–661)
Day symptom scorez 1.42 (0–3)* 0.97 (0–3) 1.1 (0–3)
Night symptom scorez 0.7 (0–2) 0.45 (0–2) 0.5 (0–2)
Rescue medication (puffs/daytime)z 1.32 1.34 1.2
(0–3.36) (0–9.3) (0.04–6.0)
S-ECP (mg/l)w 16.8 (2.1–69.4)w 26.1 (2.8–120) 23.6 (2.1–120)
B-EOS (109/L)w 0.32 (0.1–1.26) 0.38 (0.1–1.67) 0.36 (0.1–1.67)
*Po0:05:wMean values (ranges) are presented.zMedian values (ranges) are presented.
1048 E.-M. Karjalainen et al.
ARTICLE IN PRESS
Table 2 Bronchial biopsy results.
Positive cell or BM component Nonatopic asthma (n ¼ 16 21) Atopic asthma (n ¼ 47 54) All (n ¼ 63 74)
AA1* 86714 99712 9679
(58, 115) (75, 123) (77, 115)
BERMAC 255743 228723 236720
(166, 345) (183, 274) (196, 276)
CD3* 6027123 501748 529748
(344, 859) (404, 598) (432, 627)
CD4* 262757 237725 244723
(142, 383) (186, 288) (197, 290)
CD8* 187732 246726 231721
(120, 255) (195, 298) (189, 273)
EG2* 114723 99712 103711
(63, 164) (75, 123) (82, 125)
ELA* 37710 4075 3975
(17, 57) (29, 505) (29, 48)
IL4 73719 7279 7278
(34, 111) (54, 90) (56, 89)
Tenascinw 6.371.2z 7.670.3 7.270.3
(5.7, 6.9) (6.9, 8.2) (6.7, 7.7)
Abbreviations: AA1¼ tryptase positive mast cells, BerMac¼macrophages, CD3¼T-lymphocytse, CD4¼ helper T-lymphocytse,
CD8¼ suppressor T-lymphocytes, EG2¼ activated eosinophils, ELA¼ neuthophils, IL4¼ interleukin-4-positive cells.Results are
given as mean with standard error of mean (95% confidence interval), and expressed as *cells/mm2 or as wmm of
immunoreactive thickness of BM.
zP ¼ 0:007 when compared with atopic asthma.
Tenascin layer thickness





min -[ lower quartile - median - upper quartile ]- max
Figure 1 Thickness of tenascin immunoreactive band (mm) in subepithelial BM zone in atopic and nonatopic
asthmatics. Horizontal bar indicates median value.
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eosinophils and other inflammatory cells, let us
hypothesize that tenascin expression is associated
with epithelial damage caused by inflammatory
cells. In asthma epithelial damage and repair is a
complex process where a variety of cytokines and
growth factors are involved in epithelial–mesench-
ymal interaction.21 However, in this study epithelial
integrity was not investigated, and further research
is needed to study the role of tenascin in epithelial
damage. Tenascin has both adhesive and de-
adhesive properties,16 and thus it can be involved
in the epithelial shedding and restoration. Our
previous study demonstrated tenascin expression in
bronchial mucosa in asthma, but it did not show
correlation between inflammatory cells and tenas-
cin.3 However, the patients in the present study
were different as having considerably shorter
duration of the disease compared with seasonal
and chronic asthma patients studied previously.
The immunopathological differences between
nonatopic and atopic asthma are still unclear. Our
finding of similar peripheral blood eosinophil counts
in both types of asthma is in accordance with a
previous report.22 In this study, serum ECP ex-
ceeded the normal range in both nonatopic and
atopic asthma, but it was higher in atopic subjects
suggesting differences in the eosinophil function in
the two asthma phenotypes. In the present study,
serum ECP level was not associated with lung
function or BHR as has been shown earlier.23 The
finding of thicker subepithelial BM tenascin layer in
atopic asthmatics reinforces recent observations by
Amin et al.11 Correlation between BM tenascin and
inflammatory cells were more pronounced in atopic
asthma, which may indicate more uniform struc-
tural changes in atopic than in nonatopic asthma.
Both differences and similarities have been re-
ported considering the inflammatory cell and
cytokine patterns in these asthma types.10,11,24 In
the present study we found no differences in
inflammatory cell counts or IL-4-positive cells in the
bronchial mucosal level. To our knowledge this is the
largest bronchial biopsy study comparing immuno-
pathologic changes in nonatopic and atopic asth-
matics groups and therefore provides more evidence
supporting the theory of shared immunopathologic
mechanisms nonatopic and atopic asthma.
In conclusion, we have demonstrated a similar
inflammatory cell pattern in nonatopic and atopic
newly diagnosed asthma, but we have also shown
that the subepithelial BM tenascin layer is thicker
in atopic asthma. We have found shared and
distinct features in the bronchial mucosal level in
these two asthma phenotypes. We also have
ARTICLE IN PRESS
Table 3 Correlations between inflammatory cell densities and tenascin layer thickness.
Nonatopic asthma (95% CI) Atopic asthma (95% CI) All (95% CI)
EG2 0.15 0.38w 0.32w
(0.31, 0.56) (0.12, 0.59) (0.09, 0.51)
BERMAC 0.25 0.34* 0.32w
(–0.22, 0.62) (0.07, 0.56) (0.09, 0.61)
CD3 0.10 0.32* 0.27*
(–0.31, 0.56) (–0.01, 0.55) (0.04, 0.48)
CD4 0.45 0.36* 0.34w
(–0.54, 0.32) (0.08, 0.58) (0.10, 0.54)
CD8 0.55* 0.34* 0.42z
(0.07, 0.82) (0.06, 0.57) (0.19, 0.16)
AA1 0.35 0.12 0.002
(–0.41, 0.47) (–0.41, 0.47) (0.21, 0.25)
ELA 0.04 0.02 0.005
(–0.41, 0.47) (0.29, 0.26) (0.24, 0.23)
IL4 0.35 0.29* 0.29*
(0.12, 0.68) (0.002, 0.52) (0.04, 0.49)
See Table 2 for abbreviations.Values are Spearman’s correlation coefficient (r) numbers (95% confidence interval for r).
*Po0:05:wPo0:01:zPo0:001:
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demonstrated a correlation between tenascin BM
layer thickness and airway inflammation. Our
observation may in part explain the induction of
this ECM protein not normally expressed in adult
tissues. However, further research is necessary to
study the role and regulatory factors of tenascin in
asthmatic inflammation.
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